Chronic Myeloid Leukemia Coverage from Every Angle

Recent News

BCR-ABL Tyrosine Kinase Inhibitor for T315I-Mutated Accelerated-Phase CML
Novel TKI Under Study in Resistant Chronic-Phase CML
PACE and OPTIC Trials Focus on Ponatinib in Resistant Chronic-Phase CML
Novel TKI Under Study in T315I-Mutated Chronic-Phase CML
Updated Label for Ponatinib in Resistant Chronic-Phase CML
ASH 2020: Mortality and Risk Factors Associated With COVID-19 in Patients With CML
Are Symptoms of Anxiety and Depression Common in TKI-Treated Patients With CML?
ASH 2020: Characterization of ETNK1 Mutations in Atypical CML
ASH 2020: Asciminib Versus Bosutinib in Chronic-Phase CML
ASH 2020: Achieving Molecular Response With Nilotinib or Dasatinib in Chronic-Phase CML
Are Newer TKIs Worth the Cost? Closer Look at Financial Burdens of CML
Outcomes After Discontinuation of Tyrosine Kinase Inhibitor Therapy for CML
Lymphoid Blast Transformation of CML: Case Study
Long-Term Benefits and Toxicity of Dasatinib in Imatinib-Resistant CML
How Sensitive Is the EUTOS ELTS Score for CML?
Newly Diagnosed CML: Link Between BMI and Outcomes?
Case Report: Leukemia Related to Therapy for Pancreatic Neuroendocrine Tumor
Is Switching TKIs Effective in Achieving Clinical Response in Chronic-Phase CML?
Rare Occurrence of Secondary CML After AML: Case Study
Search for Optimal Dose of Ponatinib for Chronic-Phase CML: Update From OPTIC Trial
Case Report of CML With T315I Mutation: Combination Therapy With Axitinib and Dasatinib
What Factors Contribute to Functional Loss of SETD2 in CML?
Prognostic Factors for Molecular Relapseā€“Free Survival in CML
SOHO 2020: TKI Discontinuation and Adherence to Practice Guidelines in Chronic-Phase CML
Discontinuing TKI Therapy in CML: Focus on Treatment-Free Remission
SARS-CoV-2 Infection and CML: Case Report of Severe Hematologic Presentation
SOHO 2020: Indian Study of Protective Potential of Imatinib Against Malaria
SOHO 2020: Predicting Treatment-Free Remission With Nilotinib in Chronic-Phase CML
Do Associated Comorbidities Affect Oxidative Stress in CML?
Case Study: Does Hemodialysis Reduce Tyrosine Kinase Inhibitor Concentration in CML?
British Society for Haematology Guideline for Management of CML
Does Time to Response Impact Outcomes in Accelerated-Phase CML?
CML and COVID-19: Treatment Lessons Learned
Imatinib-Treated CML: A Contraindication to Renal Transplantation?
Canadian Study on Treatment Choices and Outcomes for Children With CML
CML AND COVID-19: Case Report of Successful Treatment With Tocilizumab
Medication Adherence and Its Effect on Molecular Response in CML
COVID-19 and CML: Case Report Involving Febrile Neutropenia and ARDS
UK TARGET CML Study: Comparing Real-World TKI Outcomes
Update From BYOND Trial of Bosutinib in Chronic-Phase CML

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.